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Abstract 
Background 
HbA1c testing helps to reduce the risk of complications associated with diabetes mellitus 
and is accepted to be an accurate measure of long-term glycaemic control. Immediacy of 
results through point of care testing can promote early treatment intensification and 
lifestyle modification. Currently point of care (POC) testing for HbA1C is not available in 
primary health care facilities in the Western Cape.  
Aim and objectives 
The main aim was to explore the effect of POC testing for HbA1C on treatment 
intensification, patient education, glycaemic control and the amount of patients who would 
receive an annual HbA1C test. Cost implications and technical quality was also assessed. 
Methods 
This was a quasi-experimental study comparing clinics with and without POC testing over 
a period of 1-year.  This assignment reports on half of the larger study and presents data 
from two clinics. A POC machine for HbA1C was introduced at the intervention site. 150 
patients (N=300) were randomly selected from each site. Data was collected retrospectively 
from the patient records for the preceding 12 month period at baseline and follow up. A 
peer focus group at the intervention site explored experience and perceptions of staff with 
POC testing. Technical quality was assessed by monitoring compliance with internal and 
external quality control.  
Results 
There was a significant increase in the % of patients receiving an annual HbA1C (control -
8%, POC +24%; p<0.001). The turn-around time for HbA1C results was greatly reduced 
(control 38.2 days, POC 1.2 days; p<0.001). There was no effect on intensification of 
treatment or counselling. The effect on glycaemic control must be followed up later. Staff 
reported that the POC testing was feasible. There was poor compliance with quality control 
checks. There was an incremental cost to POC testing of R1451 per 100 tests. 
Conclusion 
The increase in patients having an annual HbA1C test and reduced turn-around time for 
results will hopefully result in improved feedback to patients and glycaemic control. The 
lack of a response in terms of treatment and counselling to the results suggests a degree of 
clinical inertia that should be addressed in other ways. The initial results do not suggest a 
favourable cost to benefit ratio. 
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Introduction 
 
Diabetes is a metabolic disorder which is associated with a significant morbidity and 
mortality; there are 415 million people with diabetes in the world. It is estimated that there 
will be 642 million people with diabetes in the world by 2040. [1] In addition, the impact 
will be significant in developing countries where the majority of people with diabetes will 
be 45–64 years old, typically a person's most productive working years.[2]  
 
The estimated diabetes prevalence for South Africa is 6.5% for adults aged 20-79 years 
(approximately 1.9 million of 30 million adults).[3] It is a leading cause of blindness, lower 
extremity amputation, and end-stage renal and cardiovascular disease.[4] For each of these 
micro- and macro-vascular complications, higher levels of risk have specifically been 
linked to HbA1c levels >7%; which indicates poor glycaemic control.[5][6] 
 
HbA1c is a valid measure of glycaemic control and in 1993 the Diabetes Control and 
Complications Trial (DCCT) established that the development and progression of 
complications of diabetes is closely related to HbA1c levels.[7] HbA1c is an indicator of 
long-term glycaemic control that healthcare professionals can use to make treatment 
decisions. The amount of glycated haemoglobin is directly related to the average level of 
glucose in the blood. Since circulating erythrocytes have an average half-life of 60–90 
days, HbA1c can indicate glycaemic control over a 2–3-month period.[8] For this reason 
measurement of HbA1C has been recommended as an alternative to the traditional random 
“finger prick” blood glucose level, which provides very limited information of long-term 
glucose control. 
 
National clinical guidelines from both the United States and South Africa recommend that 
glycaemic control should be defined as a HbA1c of <7%, with HbA1c levels of > 8% 
indicating a definitive need for a change in therapy.[9][10][11] Lowering HbA1C, ideally 
to less than 7%, has been shown to reduce microvascular and neuropathic complications in 
people with both type 1 and type 2 Diabetics.[12] Patients with type 2 diabetes mellitus 
with HbA1c levels >7.5% have a 2.5 to 5 fold greater relative risk of developing 
microvascular complications [7][8] and a 5 fold greater risk of developing peripheral artery 
disease.[10][11] If the patient’s HbA1c is at target and the treatment has not been altered, 
the HbA1c can be checked every six months.[3][9] If HbA1c is above the target or the 
treatment has been altered or intensified, the HbA1c should be re-checked after three 
months.[9][14] 
 
Monitoring has traditionally been via laboratory testing in primary care and in the Western 
Cape only one test is allowed per year per patient. Results from laboratory testing arrive 
after the consultation and are therefore unavailable at the time clinical decisions are made 
regarding ongoing management. Patients must then make an additional visit to receive the 
result, which creates extra workload for both patients and health workers, or return for their 
next routine appointment after 3-6 months. At this point the result may not be filed in the 
patient record and if it is available is somewhat out of date. Clinical decisions based on 
random blood glucose may be wrong a quarter of the time, which makes this approach 
difficult to justify.[15] A possible solution to this could be to ask patients to have the 
HbA1c test done when they collect their last CDU, results will then be available at the 
clinical visit. 
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Limitations have been identified in terms of treatment intensification due to traditional 
laboratory testing including long waiting periods for results and poor follow up of these 
results with patients. Point of care (POC) testing, however, provides rapid diagnostic 
information in the clinic in order to enable clinical decisions to be made at the earliest 
opportunity during patient care and treatment. The rapid processing time of POC HbA1c 
assays generates HbA1c results in minutes and provides test results during patients’ visits. 
Evidence supports that POC HbA1c testing improves glycaemic control, not only in the 
short term (less than 1.5 years), but also the long term (3.5 years), potentially delaying the 
onset and magnitude of complications from the disease.[7] In addition to improving 
glycaemic control, studies have shown that POC HbA1c testing helps improve 
communication and collaborative efforts between physicians and patients in managing the 
disease and results in positive patient satisfaction.
 
[9][12] 
 
Concerns about POC testing include feasibility and costs of introducing it in public sector 
primary care facilities in the Western Cape. Technical quality of POC testing and the effect 
on glycaemic control and treatment intensification for patients with diabetes in this setting 
also needs to be explored and that is the reason for doing this research. 
 
Aim and objectives 
This study aimed to evaluate the cost and consequences for quality of care and glycaemic 
control when introducing point of care (POC) testing for HbA1c amongst patients with type 
2 diabetes at community health centres in the Western Cape. Specific objectives were: 
 
1. To evaluate the technical quality of POC testing for HbA1c in primary care 
2. To explore the feasibility of introducing POC testing for Hba1c in primary care  
3. To evaluate the effect of POC testing for HbA1c on the percentage of patients receiving 
an annual HbA1c test  
4. To evaluate the effect of POC testing for HbA1c on treatment intensification and patient 
counselling 
5. To evaluate the effect of POC testing for HbA1c on glycaemic control as measured by 
HbA1c 
6. To evaluate the cost implications of introducing POC testing for HbA1c in primary care 
Methods 
Study design 
 
This research assignment reports on part of a larger quasi-experimental study that 
compared two intervention and two control sites. This research assignment reports on one 
of the pairs of control and intervention sites, as the other pair was co-ordinated by a 
separate registrar. The work will be integrated for publication after independent 
examination of the assignments. Data was collected at baseline and again after a 12-month 
period for comparison.  
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Setting 
 
The study took place in the Metropolitan District Health Services, which caters for patients 
with diabetes through a network of 45 community health centres.  Community health 
centres usually see patients with diabetes on a specific “club” day and can have between 
500 and 1500 patients on the club register. Patients have routine tests performed by nurses 
when they attend the club (urine, blood pressure, weight, random capillary blood glucose) 
and are then seen either by a clinical nurse practitioner, if reasonably well controlled, or by 
a doctor if poorly controlled.  HbA1c is meant to be checked once a year to assess overall 
control and the blood sample is sent away to the laboratory. The most recent audit of 
diabetes in the Metropolitan District found that 47% of patients had received an HbA1c test 
in the previous year. The result is returned to the health centre a few days later and given to 
the clerks to file in the patient record. The result is then only available when the patient is 
next reviewed. Most patients are seen routinely 3-6 monthly, but if poorly controlled may 
be seen sooner.  Well controlled patients receive pre-packaged medication from the 
Chronic Dispensing Unit and obtain their medicines directly from the pharmacy or even 
from community based support groups.  Health education is provided by the clinical nurse 
practitioners or doctors individually on an ad hoc basis. In some centres health promoters 
provide talks to the waiting room on diabetes or group diabetes education. Health 
promoters and visiting dieticians may also be referred to for individual consultations. 
Occupational therapists in some centres have also taken initiatives around patient education 
and lifestyle. 
Study population 
 
The study population included adult patients (> 18 years of age) with type 2 diabetes who 
had been attending the community health centre for treatment for at least 1-year prior to the 
study.  
Sample size calculation 
 
A sample size calculation was based on having 90% power to detect a 1% difference in 
HbA1c (SD 2.229) with a p value of 0.05 as significant.  This outcome was chosen for the 
calculation because we had accurate data on its standard deviation and it would require a 
larger sample size than was likely to be needed for the other outcomes. 
This calculation suggested that 106 patients were required in the control and intervention 
groups (total of 212). If we assume that only 40% of the patients selected will have had an 
HbA1c test in the last year then a sample of 265 is required in each arm to achieve a sample 
of 106 with an HbA1c result. In order to ensure a sufficient sample size with an HbA1c 
result we will select 300 patients in each arm or 600 in total. As this assignment reports on 
only one of the pairs the sample size in this study was 150 patients in each arm or 300 in 
total.  
 
Selection 
 
Four community health centres from Helderberg sub-district that were willing to participate 
were selected from the eight community health centres available.  Coming from the same 
sub-district they were similar in terms of the communities served and services for diabetes. 
Two health centres were selected for this part of the study: Grabouw Community Health 
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Centre (intervention) and Macassar Health Care Centre (control). Grabouw Community 
Health Centre was chosen as the intervention site as it is the clinic I work in as part of the 
Family Medicine registrar programme; it would make it easier to oversee and facilitate the 
introduction of POC testing. The intervention centres were therefore selected in terms of 
the availability of a registrar in family medicine to assist with the research at that location.  
 
At each health centre 150 patient records were randomly selected using computer generated 
random numbers from the club register for inclusion in the study. Staff members were blind 
as to which patients were selected.   
 
Intervention 
 
A Siemens DCA Vantage Point of Care test (POCT) analyser was used during the study. 
The time to obtain an HBA1c result is 6 minutes and it is able to detect results within the 
range of 2.5% to 14%. It weighs 3.8kg and power requirements are 100- 240 Volts 
Amperes. 
 
 
 
At the health centre that was selected for the intervention two members of staff were 
identified to perform the POC testing. These staff members were identified with the help of 
the facility manager and chronic care team.  These staff members were trained on how to 
operate the POC machine by technicians from Siemens who provided a teaching workshop 
at Helderberg Hospital prior to installation of the POC machine for the study.   
 
The location of the POC machine and its integration into the process of care was negotiated 
with the local chronic care team so that it made sense for their specific setting. It was 
decided that the POC machine would be installed in the Chronic Care Unit at Grabouw 
Community Health Centre for the part of the study that I was involved in. Practically this 
was the best place to put the machine as we wanted to use the device in the routine 
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management of the diabetic patients who came for follow up at this clinic. Our clients with 
diabetes were organised in a “club” system. POC testing for HbA1C would form part of the 
routine “vitals” done for each patient presenting to this clinic; ensuring that each patient 
had an annual HbA1C. This ensured the least disruption to the “flow” in the clinic. The 
clinic staff agreed that this also eliminated “time wastage” for the 6 minutes that it would 
take to do the POC HbA1C as they could do other interventions such as foot and eye 
examinations and counselling during this time. 
 
When POC testing is performed it is not necessary to also perform a random blood glucose 
using the glucometer. The time taken to perform POC test is therefore offset by the time 
taken to perform random blood glucose and this will reduce the perception that this is 
additional work. In addition, the cost of performing the random blood glucose test will also 
be saved and helped to negate any additional cost of the HbA1c test strip. POC testing was 
performed according to a standardised operating procedure. The goal was to perform a 
routine HbA1c test once a year in all patients. Additional tests could be performed if the 
doctor felt it was clinically necessary. 
 
Assessment of the quality of the HbA1c results provided by the POC machine was assessed 
using internal quality control and external quality control measures. Internal quality control 
involved using normal and abnormal control reagents; the aim was to do this test twice a 
week for the first month and subsequently on a weekly basis. External quality control 
involved doing a POC test which would be compared with a laboratory HbA1c test; this 
was to be done monthly and the patient would be randomly selected from the patients 
attending the clinic on the diabetes club day. 
 
The HbA1c test result was entered into the medical record. According to local protocols, 
those with an HbA1c <8% were regarded as reasonably controlled, while those with an 
HbA1c >8% were seen as poorly controlled. Those with an HbA1c >10% were prioritised 
for intensification of treatment and/or education by the clinical nurse practitioner or doctor.   
Data collection 
 
For this part of the study data was collected at 2 intervals in order to allow a comparison of 
results over time and between the 2 facilities involved. Initially results were collected at 
baseline with the second set of data being collected after the POC testing machine had been 
in operation at the intervention site for 12 months. The following data was collected from 
the medical records and then again retrospectively after the one year period. Data was 
collected from the medical records using a standardised data collection form. 
 
Data Collected at Baseline: 
 
 Demographic data at baseline (age, sex) 
 Clinical data at baseline (type of diabetes, other co-morbid conditions or 
complications, random blood glucose, weight, blood pressure, total cholesterol, 
creatinine, proteinuria) 
Data Collected at Baseline and Follow Up 
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 Number of HbA1c tests performed in the previous 12 months 
 Last HbA1c test result (in prior 12 months) 
 Medication prescribed at baseline and at 12 months (Metformin, Glibenclamide, 
Gliclazide, Insulin) 
 Dose of medications prescribed at baseline and at 12 months 
 Referral for diabetes counselling recorded during previous 12 months (this is from 
the practitioner to another counsellor in or outside the health centre such as a health 
promoter or dietician. 
 Recording of diabetes counselling during consultations during previous 12 months 
by the practitioner 
After the chronic care team had used the POC testing machine for 12 months a focus group 
interview was held with them to explore their experience of using the POC machine. The 
chronic care team included one of the family physicians who worked at Grabouw 
Community Health Centre as well as the nursing staff who were trained in using the POC 
machine. The invitation to attend the interview was also extended to the facility manager 
but he was unable to attend. The interview was held at Grabouw Community Health Centre 
in September 2014 and was conducted in English. The interview was facilitated by an 
independent research assistant who was also a registrar in family medicine. This focus 
group interview was semi-structured with an interview guide and explored the practical 
issues faced in introducing and using the POC machine, the perceived impact on the quality 
of care, and the perceived cost implications. The interview was audio recorded.  
 
The cost of POC testing was determined by directly observing the time taken to perform 
the test and by obtaining the costs of the equipment and materials used to perform and 
record the test. The cost saved of any materials that were not used (i.e. random blood 
glucose strips) was also determined. The cost of the laboratory test was also determined for 
comparison. 
 
Data analysis 
 
The primary outcome of the study was the difference in % of patients who received an 
HbA1c test to accurately determine their glycaemic control in the last 12 months.  
 
Secondary outcomes included: 
 Difference in % of patients receiving more than one HbA1c test in the previous 12 
months 
 Difference in treatment intensification as measured by the % of patients started on 
a new medication to lower glucose 
 Difference in treatment intensification as measured by the difference in mean dose 
of Metformin, Glibenclamide, Gliclazide, or Insulin  
 Difference in the % of patients referred for counselling (diabetes health education) 
 Difference in the % of patients with counselling recorded in the consultation 
 Difference in the mean HbA1c result  
Data was then entered into an excel spread sheet by the researcher and checked for any 
errors. Data analysis was performed by the Biostatistics Unit at Stellenbosch University 
using the Strata Version 13 analysis program.  
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Descriptive statistics were used to report continuous data as means with standard deviation 
and to report categorical data as frequencies and percentages. Inferential statistics were 
used to compare paired data at baseline and follow up.  Normally distributed continuous 
data was analysed using a t-test and if not normally distributed using Two-sample 
Wilcoxon rank-sum (Mann-Whitney) test. Categorical data was compared using Pearson’s 
Chi Square Test. Statistical significance was determined as p < 0.05. 
The costs of testing was analysed based on the time taken to perform the test and the salary 
of the nurse performing the test as well as the costs of all materials used.  These costs were 
compared to any costs saved in terms of not performing the laboratory test and random 
blood glucose. 
 
The single qualitative data source was transcribed verbatim and checked against the 
original audio recording. The data was then analysed using the framework method 
(familiarisation, thematic index, and coding, charting, interpretation) and interpreted in 
terms of the range and nature of opinions, any associations between opinions or 
explanations for particular viewpoints held.  
Ethical considerations 
 
Ethical approval was obtained from the Health Research Ethics Committee at Stellenbosch 
University with Reference number N13/02/026. The Department of Health and the facility 
managers of the involved Community Health Centres gave permission for the study to be 
conducted at the selected sites. 
Results 
Three hundred patients with type 2 diabetes were randomly selected from two community 
health centres: 150 from the control site (Macassar Community Health Clinic) and 150 
from the intervention site (Grabouw Community Health Centre). Tables 1 and 2 present the 
baseline profile of this sample with their key diabetes indicators, known co-morbidities and 
complications. 
 
Table 1: Profile of study sample at baseline 
 
Variable All  
N=300 
 
Intervention 
N=150 
 
Control 
N=150 
 
Male: n (%) 
 
95 (31.7) 
 
48 (32.0) 
 
47 (31.3) 
 
Female: n (%) 205 (68.3) 
 
102 (68.0) 
 
103 (68.7) 
Mean age: years (SD) 55.6 (13.2)  
 
53.6 (12.9) 
 
57.6 (13.3) 
Mean BMI: kg/m2 (SD) 31.2 (6.6) 
 
31.9 (5.5) 
 
30.8 (7.0) 
 
Mean weight: kg (SD) 80.2 (17.5) 
 
80.3 (17.4) 80 (17.7) 
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Mean systolic blood 
pressure: mmHg (SD) 
142.9 (26.3) 
 
148.8 (28.0) 
 
137 (23.0) 
 
Mean diastolic blood 
pressure: mmHg (SD) 
81.6 (12.0) 
 
82.6 (13.8) 
 
80.6 (9.9) 
 
Mean serum creatinine: 
umol/l (SD) 
86.5 (70.0) 
 
71.9 (34.1) 
 
96.4 (85.1) 
 
Mean serum cholesterol: 
mmol/l (SD) 
5.2 (1.4) 
 
5 (1.2) 
 
5.3 (1.6) 
 
Mean HGT: mmol/l (SD) 10.5 (5.0) 
 
11.4 (5.6) 
 
9.5 (4.1) 
 
Mean HbA1c: % (SD) 
 
9.9 (2.8) 
 
9.9 (2.6) 
 
9.9 (3.0) 
 
 
Table 2: Known co-morbidities and complications in the study sample  
 
Co-morbidities and 
complications 
Total 
N=300 
n (%) 
Intervention  
N=150 
n (%) 
Control  
N=150 
n (%) 
 
Hypertension 217 (93.1) 90 (84.9) 127 (100) 
Hypercholesterolaemia 62 (71.3) 22 (46.8) 40 (100) 
Retinopathy 14 (4.7) 4 (2.7) 10 (6.8) 
Cataracts 4 (1.4) 2 (1.3) 2 (1.4) 
Peripheral Neuropathy 14 (4.7) 3 (2.0) 11 (7.4) 
Foot Ulcers 9 (3.0) 1 (0.7) 8 (5.4) 
Amputation 5 (1.7) 1 (0.7) 4 (2.7) 
Nephropathy 23 (7.7) 4 (2.7) 19 (12.8) 
Cardio Vascular Accident 13 (4.4) 2 (1.3) 11 (7.4) 
Ischaemic Heart Disease                                             17 (5.7) 5 (3.4) 12 (8.1) 
Congestive Cardiac 
Failure 
22 (7.4) 5 (3.4) 17 (11.5) 
 
Tables 3 present the results for the control and intervention groups for the key outcome 
variables at baseline and follow up. Table 4 compares the change from baseline to follow 
up for the two groups where there was paired data and whether there was any statistically 
significant difference. When the groups were compared at follow up there was a significant 
difference in turn-around time (control group mean of 38.1 days (SD 29.2), intervention 
group mean of 1.2 days (SD10.4); p<0.001). 
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Table 3: Measurement of outcomes at baseline and follow up in control and intervention groups 
 
Variable Control  
baseline 
N=150 
 
Control  
follow up 
N=150 
 
 
Intervention 
baseline 
N=150  
Intervention  
follow up 
N=150 
 
 
HbA1c Results 
 
Frequency of HbA1C 
testing in last year n (%) 
 
73 ( 48.7) 
 
61 (40.7)  
 
49 (32.7) 85 (56.7)  
Frequency of more than 
one HbA1C test in last 
year n (%) 
 
2 (1.3) 
 
3 (2.0) 
 
0 (0.0) 
 
10 (6.7)  
 
Turn around time for 
HBA1c result mean days 
(SD) 
52.3 (57.7) 38.2 (29.9) 56.7 (73.1) 1.2 (10.4) 
 
Treatment Intensification 
 
Frequency of prescribing 
Metformin n (%) 
123 (82.0) 97 (84.4) 132 (88.6) 119 (89.5) 
Frequency of prescribing 
Gliclazide n (%) 
67 (44.67) 61 (53.0) 78 (52.70) 77 (57.9) 
Frequency of prescribing 
Protophane n (%) 
16 (10.67) 15 (13.6) 28 (18.8) 28 (21.7) 
Frequency of prescribing 
Actraphane n (%) 
39 (26.0) 26 (22.8) 25 (16.8) 24 (18.6) 
 
Lifestyle Modification 
 
Referral for counselling n 
(%) 
 
27 (18.4) 
 
53 (38.7) 
 
21 (14.1) 
 
25 (19.1) 
 
Counselled in consultation 
n (%) 
 
82 (55.8) 
 
99 (72.3)  
 
55 (36.9) 
 
88 (66.7)  
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Table 4: Comparison of control and intervention groups for the change from baseline to follow up 
 
Variable Change in control 
Diff [N] (SD) or 
n/N (%)* 
Change in 
intervention 
Diff [N] (SD) or n/N 
(%)* 
p-value 
 
 
HbA1C Results 
 
Change in frequency of 
HbA1C testing (change in 
%) 
-12/150 (-8.0) 36/150 (24.0) <0.001 
Change in frequency of more 
than one HbA1C test 
(change in %) 
1/150] (0.7) 10/150 (6.7) 0.053 
Change in mean HbA1C 
(HbA1c %) 
 
-0.2 [26] (2.1) -0.01 [26] (1.7) 0.740 
 
Change in Treatment Intensification 
 
Change in mean dose of 
Metformin (mg) 
-1132.4 [51] 
(1355.0) 
 
-816.2 [34] (1299.1)  
 
0.209 
 
Change in mean dose of 
Gliclazide (mg) 
-38.1 [32] (176.4) -4 [20] (179.8)  
 
0.350 
 
Change in mean dose of 
Protophane  
(IU/ml)  
-6.9 [14] (27.5)  
 
-2.9 [11] (13.5)  
 
0.912 
 
Change in means dose of 
Actraphane (IU/ml)  
-29.6 [26] (35.9) -1.2 [10] (47.0)  
 
0.152 
Change in frequency of 
prescribing Metformin (% 
change)  
-4/115 (-3.5)  
 
-2 [133] (-1.5)  
 
0.313 
 
Change in frequency of 
prescribing Gliclazide (% 
change) 
6/115 (5.2) 
 
4 [132] (3.0)  
 
0.108 
 
Change in frequency of 
prescribing Protophane (% 
change)  
4/114 (3.5)  
 
2 /129 (1.6)  
 
0.555 
 
Change in frequency of 
prescribing Actraphane (% 
change) 
-2/114 (-1.8)  
 
2 /129 (1.6)  
 
0.162 
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Comparison in Change of Lifestyle Modification 
 
Change in frequency of 
referral for counselling (% 
change) 
27 [134] (20.2) 
 
6 [130] (4.6) 
 
<0.001 
 
Change in frequency of 
counselling in consultation 
(% change) 
23 [134] (17.2) 
 
34 [131] (26.0) 
 
0.184 
 
For continuous data: Diff = change in the mean; N=number of patients with paired data; 
SD=standard deviation of the change in mean 
For categorical data: n=number of patients that changed; N=number of patients with paired 
data, %= % of patients that changed 
 
 
Technical Quality 
 
A total of 54 tests for internal quality control were expected to be done throughout the 12 
month period (2 weekly in first month and then weekly for the other 11 months). Only 15 
tests were performed, which equates to 29% of the expected tests. Of the tests done all 
(100%) were within the acceptable range. The acceptable range for normal control was 
HBA1c 4.2% to 6.4% while the range for abnormal control was HBA1c 8.9% to 13.3%. 
The NHLS has major concerns about maintenance and calibration of equipment used for 
POC testing, and these findings would justify their concern.  
 
Only 2 out of the 12 (17%) expected tests for external quality control were performed. 
These two tests were well correlated (9.8mmol/l for laboratory vs. 10mmol/l for POC; and 
7 mmol/l vs. 7 mmol/l). There was insufficient data for a statistical correlation to be 
analysed. 
Costing 
The additional costs of testing were analysed based on the additional time taken to perform 
the test and the salary of the nurse performing the test as well as the costs of all additional 
materials used (Table 7).  These costs were compared to costs saved in terms of not 
performing the laboratory test and random blood glucose (Table 8). Costs were 
extrapolated to costs for 100 tests and the final incremental cost calculated as the additional 
costs of testing minus the costs saved. 
 
Table 7: Cost of performing 100 HbA1c tests using the Point of Care Machine 
Item Cost per unit for 
calculation 
Rand 
Cost of 100 tests 
Rand 
POCT Analyser (with 
lifespan of 7.5 years) 
24200 3227 
Cartridges 68 6800 
Lancets 2.28 228 
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Incremental salary cost 
to perform test if other 
tasks are performed 
and testing only 
requires 3.5 minutes of 
a staff nurse’s time 
 
6.71 
 
671.24 
 
Total cost  109.97 10996.47 
Table 8: Costs saved if HBA1c tests performed by POC testing 
Item Cost per unit for 
calculation 
Rand 
Cost for 100 tests 
Rand 
Laboratory HbA1c test 87.69 8769.00 
Blood glucose machine 
test strips 
2.90 290.00 
10 ml syringes 0.33 33.00 
Needles 0.10 10.00 
Tubes 0.00 0.00 
Salary costs taken to do 
finger prick blood 
glucose test on average 
it takes 2 minutes to do 
this test 
 
3.84 
 
 
383.57 
Total Cost  9544.97 
 
This calculation is based on the assumption that regardless of the POC machine being 
available to perform HbA1c tests, an annual Creatinine and Cholesterol blood test would 
still have to be performed. So currently the costs of performing a blood test as well as the 
transportation of them will not be saved. The annual HbA1c test is usually taken at the 
same time as the Creatinine and Cholesterol serum tests but money will be saved when a 
HbA1c test is requested on more than one occasion during the year in order to assess 
glycaemic control. The Glucometer is also a valuable tool for the acute management of 
complications associated with diabetes and would therefore still be required.  
 
Overall POC testing was R1451,50 more expensive per 100 tests performed when 
calculations are based on the assumptions above. A significant reduction in the costs of the 
cartridges use for POC testing may be possible if there is a large scale “roll-out” of POC 
testing and equipment and cartridges are bought in bulk on tender. This could significantly 
reduce the incremental costs of the test. We also anticipate that the future POC machines 
will be able to do multiple tests (such as Creatinine and Cholesterol levels) thereby further 
decreasing the costs of formal testing. 
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Themes from qualitative interview 
 
The interview group consisted of two members of the chronic care team namely the senior 
Family Physician who was involved in patient care and the Professional Nurse who was 
trained to work with the POC machine on a daily basis. The interview was recorded and 
transcribed by a professional transcriber appointed by the University of Stellenbosch. 
 
Generally there was a positive response in the interview towards POC testing for HbA1c.  
The perception that the wait time for HbA1c test result was greatly reduced from traditional 
formal blood testing was the most prominent benefit expressed. 
 
 “It saves time” 
 
“The patients’ results are available immediately” 
 
In terms of organisation the 6 minutes that the test took to execute allowed for foot and eye 
screening, which was often previously neglected.  
 
“While the patients wait for their result, you can do their feet or you can do their 
eyes, test their urine.  I could do any other stuff on the diabetic patients, whilst they 
were waiting for the result, because the result takes 6 minutes.” 
 
The usage of the POC machine for HbA1c testing led to the formulation of a “register” in 
which all the HbA1c test results done with the POC machine were recorded. The “register” 
served as a reference resource that health care professionals were able to consult and this 
was believed to be a very positive contribution in terms of clinical governance. Patients 
who had abnormally high HbA1c results and who were “missed” in terms of referral could 
be identified. 
 
“Sister Adonis has created a register which I can consult and have a look and pick 
up those results that are above a certain level, just to make sure that those are all 
being identified . So that I’ve seen as a very positive contribution” 
 
The staff felt that the machine was very easy to use especially after training.  
 
“this machine…. it just is very easy.  It’s quick and it’s fast, and it’s easy.” 
 
The test was described as “a good visual motivator to modify lifestyle habits” and it was 
believed to make a significant difference in improving glycaemic control as it “engaged the 
patient in the process of glycaemic control”. Immediate test results made it easier to 
convey the importance of glycaemic control to the patient as the long wait-time for formal 
blood test results was reduced.  
 
“If you do a test, and the result comes back three months later, the connection 
between pricking the finger and the urgency in what you’re looking for is lost, to an 
extent. I think the meaning for the patient is possibly easier to convey the 
importance of what one is dealing with.”   
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“In general, I think the test is a very powerful test, because if we tell somebody 
now, as you’re sitting in front of me, “the test we’ll do will reflect the performance 
plus minus in the last three months,” that’s a very powerful statement to make.   
 
And to engage somebody in this process, because you can analyse it, you can think 
of the behaviour, you can think of the doctor’s input, and I think if it’s a test done 
amongst many, and sent away, the meaning of it is lost.“  
 
“They were very positive about it, because they were waiting and they were 
watching the machine, because they want to see their results. The patients were 
very interested in knowing their result now.”   
 
The patients’ experience was described as an “increased interest in knowing their result 
and a more positive feeling toward improving their health”. 
 
The Family Physician who was interviewed asked to be included in the training process as 
he felt that it was a “powerful tool in motivating lifestyle modification”. He also felt that 
“in terms of overall management and overall picture of glycaemia control at the facility the 
POC HbA1c hadn’t made that much of a difference” and suggested that follow up audits be 
done in order to assess the long-term benefit of the intervention. Problems that were 
identified in terms of logistics were that there was a period of 2 weeks during the study that 
cartridges for the machine were not available due to a delay in supply. 
 
Discussion 
 
The study showed a significant improvement in the primary outcome, which was an 
increase in the percentage of patients receiving an annual HbA1c test. As the current 
guideline is an annual HbA1c test for all patients with diabetes this is a marked 
improvement [10]. There was also no significant increase in the number of additional tests, 
which implies that health workers adhered to the local policy of one test per patient per 
year.  
A marked reduction in the turn-around time was also seen. Providing test results during 
patient visits can improve glycaemic control and potentially delay the onset and magnitude 
of complications [7]. The effect of this on glycaemic control must still be evaluated in this 
study by collecting additional data 6-months after the end of the study. The need for 
registrars to graduate precluded including this data in the research assignment, but these 
results will be available at the time of publication. 
Despite the positive outcomes above there was no impact on treatment intensification or 
counselling. The lack of improvement in treatment intensification and lifestyle 
modification can possibly be attributed to a number of issues related to patient care such as 
large patient volumes, lack of appropriate theoretical knowledge or burn out of health care 
providers [16][17][18][19]. Patient resistance to initiation of insulin therapy and fear of 
insulin administration (needles) is also an important factor that needs to be considered [20]. 
 
There was a generally positive response from the chronic care team to the POC HbA1c 
testing. Studies have shown that POC testing helps improve communication and 
collaborative efforts between physicians and patients in managing the disease [9][12]
 
and 
this was the perception of the staff who worked with the POC machine. They felt that the 
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machine was easy to operate and made a significant contribution to improving the quality 
of care. The improvement in care was attributed to the immediate availability of results, 
feedback to patients and improved clinical decision making. It was seen as evoking a 
positive response from the patients who became better “collaborators” in their own health 
care.  
 
We were unable to show a decrease in overall cost related to POC testing; in fact it appears 
to be R1451.50 more expensive per 100 tests than traditional testing. We were therefore 
unable to demonstrate savings in incremental costs. There could be a significant decrease in 
costing if the programme is “rolled out” on a larger scale and equipment is bought in bulk 
on “tender”. The potential of the POC machine to do multiple tests (including Creatinine 
and Cholesterol) could also further reduce costs. 
 
There was poor adherence to quality control measures and these would need closer 
supervision if POC testing is implemented even though the few tests that were done for this 
study suggested that the quality of POC testing was acceptable. Poor adherence to the 
quality control measures may be contributed to large patient volumes and work load and a 
lack of trained staff.  
Quality data obtained through peer interviewing may have been biased due to personal 
opinion; even though the interview was conducted by an “independent” researcher; the 
interviews included staff members who were personally involved in the research (daily 
POC testing, Quality Control testing) and this may have resulted in personal interest in 
positive feedback related to the research. 
The impact of POC testing may be related to the selection of community health centres. 
More organised or less organised chronic care teams might have responded differently to 
the provision and use of the POC tests. It is possible therefore that different results could 
have been obtained if different health centres were selected. Nevertheless it was thought 
that these health centres were typical of current organisation and quality of care in the 
public sector. The number of people interviewed was small and it is possible that other 
opinions would be obtained if a broader range of staff had been included. The final 
conclusion on the costs and consequences depends on the measurement of any effect on 
glycaemic control. At present however the initial results suggest that incremental costs may 
not be worth the measured benefits due to the lack of treatment and counselling 
intensification. 
The DOH has a service level agreement with NHLS and there is a guideline document for 
POC testing. HbA1c is not on the approved list of POC tests, if it were to be recommended 
then it would have to be proposed to a number of committees including the PPTC. 
 
Conclusion 
There was significant increase in the percentage of patients receiving an annual HbA1C test 
and in the turn-around time for receiving the results. There was no change in the number of 
patients receiving more than one test in line with current department of health policy. There 
was no effect on intensification of treatment or counselling suggesting a degree of clinical 
inertia. Further data must still be collected to determine any effect on glycaemic control. 
There was poor adherence to the quality control measures and the POC testing results in an 
estimated incremental cost of R 1451,50 per 100 tests performed. Staff were positive about 
the POC testing in terms of its feasibility and likely impact on patient’s self-management. 
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The results do not support the implementation of POC testing. Future research should 
explore whether an intervention to improve the clinical response to poor control was 
amplified or not by combination with POC testing.  
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